

WEST Search History

DATE: Friday, December 03, 2004

Hide?	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
	<i>DB=PGPB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L13	Wettendorff.in.	2
	<i>DB=EPAB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L12	AU-2003293942-A1.did.	0
<input type="checkbox"/>	L11	WO-200117551-A2.did.	0
<input type="checkbox"/>	L10	AU-2003236490-B2.did.	0
<input type="checkbox"/>	L9	EP-1210113-A2.did.	0
	<i>DB=PGPB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L8	Wettendorff.in.	2
	<i>DB=EPAB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L7	WO-2004056389-A1.did.	1
<input type="checkbox"/>	L6	WO-2004056389-A1.did.	1
	<i>DB=DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L5	Wettendorff.in.	6
<input type="checkbox"/>	L4	3DMPL	0
	<i>DB=PGPB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L3	3DMPL	11
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L2	3DMPL	5
<input type="checkbox"/>	L1	3D-MPL	104

END OF SEARCH HISTORY

Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 6 of 6 returned.

☐ 1. Document ID: AU 2003293942 A1, WO 2004056389 A1

L5: Entry 1 of 6

File: DWPI

Jul 14, 2004

DERWENT-ACC-NO: 2004-500265

DERWENT-WEEK: 200474

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: A composition comprising human papilloma virus (HPV) 16 and HPV 18 virus-like particles (VLPs), useful in preparing a medicament for preventing infection caused by one or more oncogenic HPV types, excluding types HPV 16 and HPV 18

INVENTOR: DUBIN, G; INNIS, B ; SLAUI, M M ; WETTENDORFF, M A C

PRIORITY-DATA: 2003US-496653P (August 20, 2003), 2002US-435035P (December 20, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003293942 A1</u>	July 14, 2004		000	A61K039/12
<u>WO 2004056389 A1</u>	July 8, 2004	E	033	A61K039/12

INT-CL (IPC): A61 K 39/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	FIGS	Draw Ds
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	---------

☐ 2. Document ID: AU 2003218787 A1, WO 2003077942 A2

L5: Entry 2 of 6

File: DWPI

Sep 29, 2003

DERWENT-ACC-NO: 2003-779087

DERWENT-WEEK: 200432

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 or HPV 45 genotypes, useful for preventing or treating HPV infection or cervical cancer

INVENTOR: WETTENDORFF, M A C

PRIORITY-DATA: 2002GB-0006360 (March 18, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003218787 A1</u>	September 29, 2003		000	A61K039/12
<u>WO 2003077942 A2</u>	September 25, 2003	E	033	A61K039/12

INT-CL (IPC): A61 K 39/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Summary	Claims	KMC	Draw D.
------	-------	----------	-------	--------	----------------	------	-----------	----------	---------	--------	-----	---------

□ 3. Document ID: AU 2003236490 B2, WO 200117551 A2, AU 200077751 A, BR 200014171 A, EP 1210113 A2, NO 200201116 A, CZ 200200843 A3, KR 2002027630 A, HU 200202804 A2, JP 2003508495 W, CN 1387443 A, NZ 517621 A, MX 2002002484 A1, NO 200303715 A, AU 766494 B, CA 2443214 A1, JP 2004067696 A, KR 2003087081 A, AU 2003236490 A1, EP 1410805 A1, ZA 200201810 A, US 20040126394 A1, ZA 200306402 A

L5: Entry 3 of 6

File: DWPI

Aug 19, 2004

DERWENT-ACC-NO: 2001-226727

DERWENT-WEEK: 200474

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Vaccine composition comprising a herpes simplex virus antigen and a human papillomavirus antigen, useful in the treatment or prophylaxis of human papillomavirus infections and herpes simplex virus infections

INVENTOR: WETTENDORFF, M A C; WETTENDORFF, M

PRIORITY-DATA: 1999GB-0021146 (September 7, 1999), 2003AU-0236490 (August 27, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003236490 B2</u>	August 19, 2004		000	A61K039/00
<u>WO 200117551 A2</u>	March 15, 2001	E	042	A61K039/00
<u>AU 200077751 A</u>	April 10, 2001		000	A61K039/00
<u>BR 200014171 A</u>	May 21, 2002		000	A61K039/00
<u>EP 1210113 A2</u>	June 5, 2002	E	000	A61K039/295
<u>NO 200201116 A</u>	April 30, 2002		000	A61K000/00
<u>CZ 200200843 A3</u>	August 14, 2002		000	A61K039/00
<u>KR 2002027630 A</u>	April 13, 2002		000	A61K039/295
<u>HU 200202804 A2</u>	December 28, 2002		000	A61K039/295
<u>JP 2003508495 W</u>	March 4, 2003		044	A61K039/23
<u>CN 1387443 A</u>	December 25, 2002		000	A61K039/295
<u>NZ 517621 A</u>	September 26, 2003		000	A61K039/295
<u>MX 2002002484 A1</u>	September 1, 2002		000	A61K039/295
<u>NO 200303715 A</u>	April 30, 2002		000	A61K039/12
<u>AU 766494 B</u>	October 16, 2003		000	A61K039/00
<u>CA 2443214 A1</u>	March 15, 2001	E	000	A61K039/39
<u>JP 2004067696 A</u>	March 4, 2004		023	A61K039/23
<u>KR 2003087081 A</u>	November 12, 2003		000	A61K039/295
<u>AU 2003236490 A1</u>	September 18, 2003		000	A61K039/00
<u>EP 1410805 A1</u>	April 21, 2004	E	000	A61K039/295
<u>ZA 200201810 A</u>	May 26, 2004		059	A61K000/00
<u>US 20040126394 A1</u>	July 1, 2004		000	A61K039/295
<u>ZA 200306402 A</u>	October 27, 2004		040	A61K000/00

766494 B , CA 2443214 A1 , JP 2004067696 A INT-CL (IPC): A61 K 0/00; A61 K 39/00; A61 K 39/002; A61 K 39/12; A61 K 39/23; A61 K 39/245; A61 K 39/25; A61 K 39/29; A61 K 39/295; A61 K 39/39; A61 P 31/12; A61 P 31/20; A61 P 31/22; A61 P 35/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	--------

☐ 4. Document ID: ZA 200201834 A, WO 200117550 A2, AU 200072848 A, EP 1210112 A2, NO 200201115 A, BR 200014172 A, CZ 200200842 A3, KR 2002027629 A, HU 200202826 A2, JP 2003508494 W, CN 1390136 A, NZ 517622 A, AU 765245 B, MX 2002002483 A1

L5: Entry 4 of 6

File: DWPI

Apr 28, 2004

DERWENT-ACC-NO: 2001-218537

DERWENT-WEEK: 200432

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Vaccine composition useful for combating papillomavirus infection, especially cervical cancer, comprises a hepatitis B viral antigen and a human papillomavirus antigen in conjunction with an adjuvant

INVENTOR: WETTENDORFF, M A C; WTTENDORFF, M A C

PRIORITY-DATA: 1999GB-0021147 (September 7, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>ZA 200201834 A</u>	April 28, 2004		062	A61K000/00
<u>WO 200117550 A2</u>	March 15, 2001	E	046	A61K039/00
<u>AU 200072848 A</u>	April 10, 2001		000	A61K039/00
<u>EP 1210112 A2</u>	June 5, 2002	E	000	A61K039/295
<u>NO 200201115 A</u>	April 30, 2002		000	A61K000/00
<u>BR 200014172 A</u>	May 14, 2002		000	A61K039/00
<u>CZ 200200842 A3</u>	August 14, 2002		000	A61K039/12
<u>KR 2002027629 A</u>	April 13, 2002		000	A61K039/295
<u>HU 200202826 A2</u>	December 28, 2002		000	A61K039/295
<u>JP 2003508494 W</u>	March 4, 2003		054	A61K039/29
<u>CN 1390136 A</u>	January 8, 2003		000	A61K039/295
<u>NZ 517622 A</u>	September 26, 2003		000	A61K039/395
<u>AU 765245 B</u>	September 11, 2003		000	A61K039/00
<u>MX 2002002483 A1</u>	September 1, 2002		000	A61K039/295

INT-CL (IPC): A61 K 0/00; A61 K 31/20; A61 K 39/00; A61 K 39/002; A61 K 39/12; A61 K 39/29; A61 K 39/295; A61 K 39/39; A61 K 39/395; A61 P 31/12; A61 P 31/20; A61 P 31/22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	--------

☐ 5. Document ID: NZ 512890 A, WO 200041463 A2, AU 200021009 A, NO 200103337 A, EP 1140163 A2, BR 9916893 A, CZ 200102544 A3, KR 2001090011 A, HU 200105070 A2, ZA 200105690 A, MX 2001007112 A1, JP 2002534438 W, CN 1391482 A, AU 760574 B

L5: Entry 5 of 6

File: DWPI

Sep 26, 2003

DERWENT-ACC-NO: 2000-490988

DERWENT-WEEK: 200366

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Treatment and prevention of hepatitis B virus infection, using an antiviral agent and a vaccine in simultaneous or sequential use

INVENTOR: ATKINSON, G F; BOON, R J ; VANDEPAPELIERE, P G ; WETTENDORFF, M A C

PRIORITY-DATA: 1999GB-0000630 (January 12, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>NZ 512890 A</u>	September 26, 2003		000	A61K039/29
<u>WO 200041463 A2</u>	July 20, 2000	E	018	A61K031/52
<u>AU 200021009 A</u>	August 1, 2000		000	A61K031/00
<u>NO 200103337 A</u>	August 17, 2001		000	A61K000/00
<u>EP 1140163 A2</u>	October 10, 2001	E	000	A61K039/29
<u>BR 9916893 A</u>	November 20, 2001		000	A61K031/00
<u>CZ 200102544 A3</u>	January 16, 2002		000	A61K009/20
<u>KR 2001090011 A</u>	October 17, 2001		000	A61K031/70
<u>HU 200105070 A2</u>	April 29, 2002		000	A61K031/00
<u>ZA 200105690 A</u>	September 25, 2002		042	A61K000/00
<u>MX 2001007112 A1</u>	November 1, 2001		000	A61K031/00
<u>JP 2002534438 W</u>	October 15, 2002		026	A61K045/00
<u>CN 1391482 A</u>	January 15, 2003		000	A61K039/29
<u>AU 760574 B</u>	May 15, 2003		000	A61K031/00

INT-CL (IPC): A61 J 1/03; A61 K 0/00; A61 K 9/20; A61 K 31/00; A61 K 31/513; A61 K 31/52; A61 K 31/522; A61 K 31/662; A61 K 31/70; A61 K 31/7052; A61 K 31/7056; A61 K 31/7076; A61 K 38/21; A61 K 39/00; A61 K 39/29; A61 K 39/39; A61 K 45/00; A61 P 1/16; A61 P 5/00; A61 P 31/20; C12 N 0/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	--------

☐ 6. Document ID: TW 580393 A, WO 9945957 A2, AU 9933283 A, NO 200004487 A, BR 9908599 A, EP 1064025 A2, ZA 9901829 A, CZ 200003284 A3, HU 200101047 A2, CN 1299288 A, KR 2001041629 A, MX 2000008817 A1, JP 2002506045 W, AU 750720 B, US 6451320 B1, NZ 506602 A, US 20030129199 A1

L5: Entry 6 of 6

File: DWPI

Mar 21, 2004

DERWENT-ACC-NO: 1999-551216

DERWENT-WEEK: 200458

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New vaccine compositions containing a hepatitis B viral antigen, a herpes simplex viral antigen and an adjuvant which is a preferential stimulator of a TH1 cell response

INVENTOR: STEPHENNE, J; WETTENDORFF, M A C

PRIORITY-DATA: 1998GB-0013561 (June 23, 1998), 1998GB-0005105 (March 9, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>TW 580393 A</u>	March 21, 2004		000	A61K039/295
<u>WO 9945957 A2</u>	September 16, 1999	E	038	A61K039/295
<u>AU 9933283 A</u>	September 27, 1999		000	A61K039/295
<u>NO 200004487 A</u>	October 19, 2000		000	A61K000/00
<u>BR 9908599 A</u>	November 14, 2000		000	A61K039/295
<u>EP 1064025 A2</u>	January 3, 2001	E	000	A61K039/295
<u>ZA 9901829 A</u>	November 29, 2000		037	A61K000/00
<u>CZ 200003284 A3</u>	February 14, 2001		000	A61K039/295
<u>HU 200101047 A2</u>	July 30, 2001		000	A61K039/295
<u>CN 1299288 A</u>	June 13, 2001		000	A61K039/295
<u>KR 2001041629 A</u>	May 25, 2001		000	A61K039/295
<u>MX 2000008817 A1</u>	March 1, 2001		000	A61K039/295
<u>JP 2002506045 W</u>	February 26, 2002		047	A61K039/295
<u>AU 750720 B</u>	July 25, 2002		000	A61K039/295
<u>US 6451320 B1</u>	September 17, 2002		000	A61K039/295
<u>NZ 506602 A</u>	February 28, 2003		000	A61K039/295
<u>US 20030129199 A1</u>	July 10, 2003		000	A61K039/295

506602 A , US 20030129199 A1 INT-CL (IPC): A61 K 0/00; A61 K 39/00; A61 K 39/02; A61 K 39/12; A61 K 39/245; A61 K 39/25; A61 K 39/29; A61 K 39/295; A61 K 39/385; A61 K 39/39; A61 K 39/42; A61 P 31/12; A61 P 37/00; C07 K 14/02; C07 K 14/03

Full	Title	Citation	Front	Review	Classification	Date	Reference	Class. Refs	Abstract Refs	Claims	RMIC	Draw. Des
------	-------	----------	-------	--------	----------------	------	-----------	-------------	---------------	--------	------	-----------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

Wettendorff.in.

6

Display Format: CIT

Change Format

[Previous Page](#)[Next Page](#)[Go to Doc#](#)

L2 ANSWER 1 OF 9 MEDLINE on STN
 AN 2003457800 MEDLINE
 DN PubMed ID: 14520455
 TI Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.
 AU Wang S S; Schiffman M; Shields T S; Herrero R; Hildesheim A; Bratti M C; Sherman M E; Rodriguez A C; Castle P E; Morales J; Alfaro M; Wright T; Chen S; Clayman B; Burk R D; Viscidi R P
 CS National Cancer Institute, Bethesda, MD 20892-7234, USA..
 wangso@mail.nih.gov
 NC N01CP21081 (NCI)
 N01PP31061
 R01CA78527 (NCI)
 SO British journal of cancer, (2003 Oct 6) 89 (7) 1248-54.
 Journal code: 0370635. ISSN: 0007-0920.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200311
 ED Entered STN: 20031002
 Last Updated on STN: 20031218
 Entered Medline: 20031125
 AB Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n=9949), HPV-18 (n=9928), HPV-31 (n=9932), and HPV-45 (n=3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n=573). HPV-16, -18, -31, and -45 seroprevalence was 15, 15, 16, and 11%, respectively. Of women DNA-positive for HPV-16, -18, -31, or -45, seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.
 CT Check Tags: Comparative Study; Female; Human; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.
 Adolescent
 Adult
 Aged
 Aged, 80 and over
 *Antibodies, Viral: BL, blood
 Antigens, Viral: IM, immunology
 *Cervical Intraepithelial Neoplasia: EP, epidemiology
 Cervical Intraepithelial Neoplasia: VI, virology
 *Cervix Neoplasms: EP, epidemiology
 Cervix Neoplasms: VI, virology
 Cohort Studies
 Costa Rica: EP, epidemiology
 DNA, Viral: AN, analysis
 Middle Aged
 *Papillomavirus Infections: EP, epidemiology
 Papillomavirus Infections: VI, virology
 Papillomavirus, Human: GE, genetics
 *Papillomavirus, Human: IM, immunology
 Polymerase Chain Reaction
 Seroepidemiologic Studies
 CN 0 (Antibodies, Viral); 0 (Antigens, Viral); 0 (DNA, Viral)

L2 ANSWER 2 OF 9 MEDLINE on STN
 AN 2001222330 MEDLINE
 DN PubMed ID: 11312347
 TI Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.
 AU Gerber S; Lane C; Brown D M; Lord E; DiLorenzo M; Clements J D; Rybicki E; Williamson A L; Rose R C
 CS University of Rochester Medical Center, Rochester, New York 14642, USA.
 NC CA 84105-01 (NCI)
 SO Journal of virology, (2001 May) 75 (10) 4752-60.
 Journal code: 0113724. ISSN: 0022-538X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200105
 ED Entered STN: 20010529
 Last Updated on STN: 20010529
 Entered Medline: 20010524
 AB Certain human papillomaviruses (HPVs) cause most cervical cancer, which remains a significant source of morbidity and mortality among women worldwide. HPV recombinant virus-like particles (VLPs) are promising vaccine candidates for controlling anogenital HPV disease and are now being evaluated as a parenteral vaccine modality in human subjects. Vaccines formulated for injection generally are more costly, more difficult to administer, and less acceptable to recipients than are mucosally administered vaccines. Since oral delivery represents an attractive alternative to parenteral injection for large-scale human vaccination, the oral immunogenicity of HPV type 11 (HPV-11) VLPs in mice was previously investigated; it was found that a modest systemic neutralizing antibody response was induced (R. C. Rose, C. Lane, S. Wilson, J. A. Suzich, E. Rybicki, and A. L. Williamson, Vaccine 17:2129-2135, 1999). Here we examine whether VLPs of other genotypes may also be immunogenic when administered orally and whether mucosal adjuvants can be used to enhance VLP oral immunogenicity. We show that HPV-16 and HPV-18 VLPs are immunogenic when administered orally and that oral coadministration of these antigens with Escherichia coli heat-labile enterotoxin (LT) mutant R192G (LT R192G) or CpG DNA can significantly improve anti-VLP humoral responses in peripheral blood and in genital mucosal secretions. Our results also suggest that LT R192G may be superior to CpG DNA in this ability. These findings support the concept of oral immunization against anogenital HPV disease and suggest that clinical studies involving this approach may be warranted.
 CT Check Tags: Female; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
 *Adjuvants, Immunologic
 Administration, Oral
 Animals
 Antibodies, Viral: BL, blood
 Antibodies, Viral: CL, classification
 Antibody Specificity
 Bacterial Toxins: GE, genetics
 *Bacterial Toxins: IM, immunology
 *CpG Islands: IM, immunology
 Enterotoxins: GE, genetics
 *Enterotoxins: IM, immunology
 *Escherichia coli
 Immunoglobulin G: BL, blood
 Immunoglobulin G: CL, classification

Mice
 Mice, Inbred BALB C
 Mutagenesis, Site-Directed
 *Oncogene Proteins, Viral: IM, immunology
 *Papillomavirus, Human: IM, immunology
 *Vaccines, Synthetic: IM, immunology
 Vagina: IM, immunology
 *Viral Vaccines: IM, immunology
 Virion: IM, immunology

CN 0 (Adjuvants, Immunologic); 0 (Antibodies, Viral); 0 (Bacterial Toxins); 0 (Enterotoxins); 0 (Immunoglobulin G); 0 (Oncogene Proteins, Viral); 0 (Vaccines, Synthetic); 0 (Viral Vaccines); 0 (enterotoxin LT); 0 (oncogene viral capsid protein, L1 human papillomavirus type 16)

L2 ANSWER 3 OF 9 MEDLINE on STN
 AN 2001214728 MEDLINE
 DN PubMed ID: 11166904
 TI Immunological analyses of human papillomavirus capsids.
 AU Girolglou T; Sapp M; Lane C; Fligge C; Christensen N D; Streeck R E; Rose R C
 CS Institute for Medical Microbiology and Hygiene, University of Mainz, D-55101, Mainz, Germany.
 SO Vaccine, (2001 Feb 8) 19 (13-14) 1783-93.
 Journal code: 8406899. ISSN: 0264-410X.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200104
 ED Entered STN: 20010425
 Last Updated on STN: 20010425
 Entered Medline: 20010419

AB Recombinant human papillomavirus (HPV) virus-like particles (VLPs) are promising vaccine candidates for controlling anogenital HPV disease. Questions remain, however, concerning the extent of capsid antigenic similarity between closely related virus genotypes. To investigate this issue, we produced VLPs and corresponding polyclonal immune sera from several anogenital HPV types, and examined these reagents in enzyme-linked immunosorbent assays (ELISAs) and in cross-neutralization studies. Despite varying degrees of L1 genetic sequence relatedness, VLPs of each type examined induced high-titer serum polyclonal antibody responses that were entirely genotype-specific. In an in vitro infectivity assay, only cognate VLP antisera were able to neutralize pseudovirions of HPV-16, HPV-18 and HPV-33, with two exceptions: HPV-31 and HPV-45 VLP post-immune sera demonstrated low levels of neutralizing activity against pseudovirions of HPV-33 and HPV-18, respectively. In other experiments, epitopes shared between closely related types were found to be less immunogenic than, and antigenically distinct from, primary type-specific B-cell determinants of the viral capsid. In addition, results from epitope blocking experiments suggested a close correlation between primary type-specific capsid antigenic sites and virion neutralization. These findings support the view that papillomavirus genotypes denote unique viral serotypes, and suggest that a successful vaccine for these viruses will likely require the inclusion of VLPs of each serotype for which protection is desired.

CT Check Tags: Human; Support, Non-U.S. Gov't
 Absorption
 Antibodies, Monoclonal: IM, immunology
 Antibodies, Viral: IM, immunology
 *Antibody Specificity: IM, immunology
 Antigens, Viral: GE, genetics

> d 13 1-11 ti

L3 ANSWER 1 OF 11 MEDLINE on STN
TI The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.

L3 ANSWER 2 OF 11 MEDLINE on STN
TI Therapeutic vaccination.

L3 ANSWER 3 OF 11 MEDLINE on STN
TI Activation of primary allogeneic CD8+ T cells by dendritic cells generated in vitro from CD34+ cord blood progenitor cells.

L3 ANSWER 4 OF 11 MEDLINE on STN
TI FcR cross-linking on monocytes results in impaired T cell stimulatory capacity.

L3 ANSWER 5 OF 11 MEDLINE on STN
TI Anti-idiotypic cancer vaccines: pre-clinical and clinical studies.

L3 ANSWER 6 OF 11 MEDLINE on STN
TI Modulation of cancer patients' immune responses by anti-idiotypic antibodies.

L3 ANSWER 7 OF 11 MEDLINE on STN
TI Functional mimicry of tumor-associated antigens by antiidiotypic antibodies.

L3 ANSWER 8 OF 11 MEDLINE on STN
TI Modulation of cancer patients' immune responses by administration of anti-idiotypic antibodies.

L3 ANSWER 9 OF 11 MEDLINE on STN
TI Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.

L3 ANSWER 10 OF 11 MEDLINE on STN
TI Specific detection of antibodies in cancer patients following immunotherapy with anti-idiotypic.

L3 ANSWER 11 OF 11 MEDLINE on STN
TI Anti-idiotypic immunization of cancer patients: modulation of the immune response.

=> d 15 1-5

L5 ANSWER 1 OF 5 MEDLINE on STN
AN 2003155985 MEDLINE
DN PubMed ID: 12674200
TI High-dose antibiotic therapy is superior to a 3-drug combination of prostanoids and lipid A derivative in protecting irradiated canines.
AU Kumar K Sree; Srinivasan V; Toles Raymond E; Miner Venita L; Jackson William E; Seed Thomas M
CS Radiation Casualty Management Team, Armed Forces Radiobiology Research Institute, Bethesda, MD 20889, USA.. kumar@afrrri.usuhs.mil
SO Journal of radiation research, (2002 Dec) 43 (4) 361-70.
Journal code: 0376611. ISSN: 0449-3060.
CY Japan
DT (EVALUATION STUDIES)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200304
ED Entered STN: 20030404
Last Updated on STN: 20030426
Entered Medline: 20030425

L5 ANSWER 2 OF 5 MEDLINE on STN
AN 2002640668 MEDLINE
DN PubMed ID: 12399191
TI The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
AU Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
CS Interdisciplinaire Dienst voor het Welzijn, IDEWE, Leuven, Belgium.
SO Vaccine, (2002 Nov 1) 20 (31-32) 3644-9.
Journal code: 8406899. ISSN: 0264-410X.
CY Netherlands
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals
EM 200305
ED Entered STN: 20021026
Last Updated on STN: 20030531
Entered Medline: 20030530

L5 ANSWER 3 OF 5 MEDLINE on STN
AN 2002351230 MEDLINE
DN PubMed ID: 12057618
TI Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant.
AU Desombere Isabelle; Van der Wielen Marie; Van Damme Pierre; Stoffel Michel; De Clercq Norbert; Goilav Christian; Leroux-Roels Geert
CS Centre for Vaccinology, Ghent University Hospital, De Pintelaan 185 9000, Ghent, Belgium.
SO Vaccine, (2002 Jun 7) 20 (19-20) 2597-602.
Journal code: 8406899. ISSN: 0264-410X.
CY England: United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA English
FS Priority Journals

EM 200211
ED Entered STN: 20020704
Last Updated on STN: 20021214
Entered Medline: 20021127

L5 ANSWER 4 OF 5 MEDLINE on STN

AN 2000113866 MEDLINE

DN PubMed ID: 10649617

TI A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

AU McCormack S; Tilzey A; Carmichael A; Gotch F; Kepple J; Newberry A; Jones G; Lister S; Beddows S; Cheingsong R; Rees A; Babiker A; Banatvala J; Bruck C; Darbyshire J; Tyrrell D; Van Hoecke C; Weber J

CS Department of Virology, St Thomas' Hospital (UMDS), London, UK.

SO Vaccine, (2000 Jan 18) 18 (13) 1166-77.

Journal code: 8406899. ISSN: 0264-410X.

CY ENGLAND: United Kingdom

DT (CLINICAL TRIAL)

(CLINICAL TRIAL, PHASE I)

Journal; Article; (JOURNAL ARTICLE)

(RANDOMIZED CONTROLLED TRIAL)

LA English

FS Priority Journals; AIDS

EM 200003

ED Entered STN: 20000330

Last Updated on STN: 20000330

Entered Medline: 20000322

L5 ANSWER 5 OF 5 MEDLINE on STN

AN 1999345239 MEDLINE

DN PubMed ID: 10418898

TI The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.

AU Moore A; McCarthy L; Mills K H

CS Department of Biology, National University of Ireland, Maynooth, Co. Kildare.

SO Vaccine, (1999 Jun 4) 17 (20-21) 2517-27.

Journal code: 8406899. ISSN: 0264-410X.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; AIDS

EM 199908

ED Entered STN: 19990910

Last Updated on STN: 19990910

Entered Medline: 19990826

L12 ANSWER 1 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
 AN 2003:212478 BIOSIS
 DN PREV200300212478
 TI High-dose antibiotic therapy is superior to a 3-drug combination of
 prostanoids and lipid A derivative in protecting irradiated canines.
 AU Kumar, K. Sree [Reprint Author]; Srinivasan, V.; Toles, Raymond E.; Miner,
 Venita L.; Jackson, William E.; Seed, Thomas M.
 CS United States Military Cancer Institute, Washington, D.C., USA
 kumar@afrrri.usuhs.mil
 SO Journal of Radiation Research, (December 2002) Vol. 43, No. 4, pp.
 361-370. print.
 CODEN: JRARAX. ISSN: 0449-3060.
 DT Article
 LA English
 ED Entered STN: 30 Apr 2003
 Last Updated on STN: 30 Apr 2003

L12 ANSWER 2 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
 AN 2003:390 BIOSIS
 DN PREV200300000390
 TI The immunogenicity and reactogenicity profile of a candidate hepatitis B
 vaccine in an adult vaccine non-responder population.
 AU Jacques, P.; Moens, G. [Reprint Author]; Desombere, I.; Dewijngaert, J.;
 Leroux-Roels, G.; Wettendorff, M.; Thoelen, S.
 CS Interdisciplinaire Dienst voor het Welzijn, IDEWE, Leuven, Belgium
 guido.moens@idewe.be
 SO Vaccine, (1 November 2002) Vol. 20, No. 31-32, pp. 3644-3649. print.
 ISSN: 0264-410X (ISSN print).
 DT Article
 LA English
 ED Entered STN: 18 Dec 2002
 Last Updated on STN: 18 Dec 2002

L12 ANSWER 3 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
 AN 2002:582887 BIOSIS
 DN PREV200200582887
 TI Combined hepatitis and herpesvirus antigen compositions.
 AU Stephenne, Jean [Inventor, Reprint author]; Wettendorff, Martine Anne
 Cecile [Inventor]
 CS Rixensart, Belgium
 ASSIGNEE: SmithKline Beecham Biologicals S.A., Rixensart, Belgium
 PI US 6451320 September 17, 2002
 SO Official Gazette of the United States Patent and Trademark Office Patents,
 (Sep. 17, 2002) Vol. 1262, No. 3. [http://www.uspto.gov/web/menu/patdata.ht](http://www.uspto.gov/web/menu/patdata.htm)
 ml. e-file.
 CODEN: OGUPE7. ISSN: 0098-1133.
 DT Patent
 LA English
 ED Entered STN: 13 Nov 2002
 Last Updated on STN: 13 Nov 2002

L12 ANSWER 4 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
 AN 2002:385622 BIOSIS
 DN PREV200200385622
 TI Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04,
 a hepatitis B vaccine with a novel adjuvant.
 AU Desombere, Isabelle; Van Der Wielen, Marie; Van Damme, Pierre; Stoffel,
 Michel; De Clercq, Norbert; Goilav, Christian; Leroux-Roels, Geert
 [Reprint author]
 CS Centre for Vaccinology, Ghent University Hospital, De Pintelaan 185, 9000,

Ghent, Belgium
geert.lerouxroels@rug.ac.be

SO Vaccine, (7 June, 2002) Vol. 20, No. 19-20, pp. 2597-2602. print.
CODEN: VACCDE. ISSN: 0264-410X.
DT Article
LA English
ED Entered STN: 17 Jul 2002
Last Updated on STN: 17 Jul 2002

L12 ANSWER 5 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:314082 BIOSIS
DN PREV200200314082
TI Adjuvant compositions for vaccines.
AU Boon, Thierry [Inventor, Reprint author]; Silla, Silvia [Inventor];
Uyttenhove, Catherine [Inventor]
CS Brussels, Belgium
ASSIGNEE: SmithKline Beecham Biologicals s.a., Rixensart, Belgium
PI US 6375945 April 23, 2002
SO Official Gazette of the United States Patent and Trademark Office Patents,
(Apr. 23, 2002) Vol. 1257, No. 4. <http://www.uspto.gov/web/menu/patdata.html>. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 29 May 2002
Last Updated on STN: 29 May 2002

L12 ANSWER 6 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2000:93059 BIOSIS
DN PREV200000093059
TI A phase I trial in HIV negative healthy volunteers evaluating the effect
of potent adjuvants on immunogenicity of a recombinant gp120W61D derived
from dual tropic R5X4 HIV-1ACH320.
AU McCormack, S. [Reprint author]; Tilzey, A.; Carmichael, A.; Gotch, F.;
Kepple, J.; Newberry, A.; Jones, G.; Lister, S.; Beddows, S.; Cheingsong,
R.; Rees, A.; Babiker, A.; Banatvala, J.; Bruck, C.; Darbyshire, J.;
Tyrrell, D.; Van Hoecke, C.; Weber, J.
CS HIV Division, Medical Research Council Clinical Trials Unit, 222 Euston
Road, London, NW1 2DA, UK
SO Vaccine, (Jan., 2000) Vol. 18, No. 13, pp. 1166-1177. print.
CODEN: VACCDE. ISSN: 0264-410X.
DT Article
LA English
ED Entered STN: 10 Mar 2000
Last Updated on STN: 3 Jan 2002

L12 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:346722 BIOSIS
DN PREV199900346722
TI The adjuvant combination monophosphoryl lipid A and QS21 switches T cell
responses induced with a soluble recombinant HIV protein from Th2 to Th1.
AU Moore, Anne; McCarthy, Leone; Mills, Kingston H. G. [Reprint author]
CS Infection and Immunity Group, Department of Biology, National University
of Ireland, Maynooth, Co. Kildare, Ireland
SO Vaccine, (June 4, 1999) Vol. 17, No. 20-21, pp. 2517-2527. print.
CODEN: VACCDE. ISSN: 0264-410X.
DT Article
LA English
ED Entered STN: 24 Aug 1999
Last Updated on STN: 24 Aug 1999

d his

(FILE 'HOME' ENTERED AT 08:31:48 ON 03 DEC 2004)

FILE 'MEDLINE' ENTERED AT 08:31:56 ON 03 DEC 2004

L1	638 S HPV-16 AND HPV-18
L2	9 S L1 AND VLP
	E WETTENDORFF/AU
L3	11 S E5
L4	0 S 3DMPL
L5	5 S 3D MPL
L6	0 S L5 AND PAPILLOMA
L7	14 S L1 AND VIRUS-LIKE PARTICLES
L8	0 S ADJUVANT AND L7
L9	0 S ALUMINIUM AND L7

FILE 'BIOSIS' ENTERED AT 08:43:29 ON 03 DEC 2004

L10	14 S L1 AND VIRUS-LIKE PARTICLES
L11	0 S L10 AND 3D MPL
L12	7 S 3D MPL